Maxis Berhad (KLSE:MAXIS)
Malaysia · Delayed Price · Currency is MYR 3.450
+0.010 (0.29%)
At close: Aug 1, 2025
CTI BioPharma Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 10,541 | 10,536 | 10,180 | 9,789 | 9,241 | 8,966 | Upgrade | |
Revenue Growth (YoY) | 2.77% | 3.50% | 3.99% | 5.93% | 3.07% | -3.73% | Upgrade |
Cost of Revenue | 5,842 | 5,862 | 5,715 | 5,421 | 4,957 | 4,557 | Upgrade |
Gross Profit | 4,699 | 4,674 | 4,465 | 4,368 | 4,284 | 4,409 | Upgrade |
Selling, General & Admin | 642 | 639 | 591 | 583 | 581 | 590 | Upgrade |
Other Operating Expenses | 87 | 76 | 193 | 49 | 95 | 93 | Upgrade |
Operating Expenses | 2,630 | 2,629 | 2,816 | 2,460 | 2,342 | 2,426 | Upgrade |
Operating Income | 2,069 | 2,045 | 1,649 | 1,908 | 1,942 | 1,983 | Upgrade |
Interest Expense | -458 | -461 | -453 | -418 | -459 | -477 | Upgrade |
Interest & Investment Income | 36 | 34 | 27 | 30 | 22 | 84 | Upgrade |
Currency Exchange Gain (Loss) | 1 | 1 | -6 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 250 | 258 | 227 | 282 | 257 | 262 | Upgrade |
EBT Excluding Unusual Items | 1,898 | 1,877 | 1,444 | 1,802 | 1,762 | 1,852 | Upgrade |
Pretax Income | 1,898 | 1,877 | 1,444 | 1,802 | 1,762 | 1,852 | Upgrade |
Income Tax Expense | 484 | 481 | 452 | 651 | 454 | 470 | Upgrade |
Earnings From Continuing Operations | 1,414 | 1,396 | 992 | 1,151 | 1,308 | 1,382 | Upgrade |
Minority Interest in Earnings | - | - | 1 | 1 | - | - | Upgrade |
Net Income | 1,414 | 1,396 | 993 | 1,152 | 1,308 | 1,382 | Upgrade |
Net Income to Common | 1,414 | 1,396 | 993 | 1,152 | 1,308 | 1,382 | Upgrade |
Net Income Growth | 37.82% | 40.58% | -13.80% | -11.93% | -5.36% | -8.60% | Upgrade |
Shares Outstanding (Basic) | 7,833 | 7,833 | 7,831 | 7,828 | 7,825 | 7,822 | Upgrade |
Shares Outstanding (Diluted) | 7,835 | 7,835 | 7,833 | 7,832 | 7,829 | 7,825 | Upgrade |
Shares Change (YoY) | 0.03% | 0.03% | 0.01% | 0.04% | 0.05% | 0.04% | Upgrade |
EPS (Basic) | 0.18 | 0.18 | 0.13 | 0.15 | 0.17 | 0.18 | Upgrade |
EPS (Diluted) | 0.18 | 0.18 | 0.13 | 0.15 | 0.17 | 0.18 | Upgrade |
EPS Growth | 37.41% | 40.38% | -13.74% | -11.98% | -5.48% | -8.46% | Upgrade |
Free Cash Flow | 2,073 | 2,046 | 1,675 | 1,583 | 2,130 | 2,243 | Upgrade |
Free Cash Flow Per Share | 0.27 | 0.26 | 0.21 | 0.20 | 0.27 | 0.29 | Upgrade |
Dividend Per Share | 0.160 | 0.160 | 0.160 | 0.200 | 0.160 | 0.160 | Upgrade |
Dividend Growth | - | - | -20.00% | 25.00% | - | -20.00% | Upgrade |
Gross Margin | 44.58% | 44.36% | 43.86% | 44.62% | 46.36% | 49.18% | Upgrade |
Operating Margin | 19.63% | 19.41% | 16.20% | 19.49% | 21.02% | 22.12% | Upgrade |
Profit Margin | 13.41% | 13.25% | 9.75% | 11.77% | 14.15% | 15.41% | Upgrade |
Free Cash Flow Margin | 19.67% | 19.42% | 16.45% | 16.17% | 23.05% | 25.02% | Upgrade |
EBITDA | 3,371 | 3,354 | 3,017 | 3,142 | 3,190 | 3,123 | Upgrade |
EBITDA Margin | 31.98% | 31.83% | 29.64% | 32.10% | 34.52% | 34.83% | Upgrade |
D&A For EBITDA | 1,302 | 1,309 | 1,368 | 1,234 | 1,248 | 1,140 | Upgrade |
EBIT | 2,069 | 2,045 | 1,649 | 1,908 | 1,942 | 1,983 | Upgrade |
EBIT Margin | 19.63% | 19.41% | 16.20% | 19.49% | 21.02% | 22.12% | Upgrade |
Effective Tax Rate | 25.50% | 25.63% | 31.30% | 36.13% | 25.77% | 25.38% | Upgrade |
Updated Feb 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.